- About Us
- Our Story
- Our Products
- Our Science
- Our People
- Our Citizenship
-
Investors
- Reports and Filings
- Presentations
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Governance
- Investor Services
- Media
- Partners
- Canada
- Australia
- Germany
- India
- New Zealand
- China
- Netherlands
- Spain
- Contact Us
Press Releases
Feb
- Dr. Reddy’s Recalls Prescription Drug Blister Packages Due to Risk of Poisoning
- Dr. Reddy's Laboratories announces the launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
- Dr. Reddy's initiates process for Emergency Use Authorization of Sputnik V
- Dr. Reddy's Laboratories announces the launch of Capecitabine Tablets, USP in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Vigabatrin Tablets, USP in the U.S. Market
- Dr Reddy’s is pleased to share that Sputnik V showed strong efficacy, immunogenicity and safety results in the Interim Phase-3 data on 19866 people in the clinical trial conducted by its partner, RDIF
Jan
- Dr. Reddy’s Q3 & 9M FY21 Financial Results
- Dr. Reddy’s and GRA announce Avigan Pivotal Studies Update Study for hospitalized moderate to severe cases in Kuwait terminated, while study for out-patient mild to moderate cases continues in North America
- Dr. Reddy’s receives approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India
- Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India
- Dr. Reddy's Laboratories to present at the 39th Annual J.P. Morgan Healthcare Conference
- Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market
